Home » Diabetic Gastroparesis Candidate Fails in Phase 3
Diabetic Gastroparesis Candidate Fails in Phase 3
Evoke Pharma’s drug candidate EVK-001 sunk in a Phase 3 trial assessing its use in female patients with symptomatic diabetic gastroparesis.
The candidate failed to meet its primary endpoint of symptom improvement at week four, the California-based company said.
The company said that data from multiple clinical sites revealed patient improvement, but this was not consistent among all study locations.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May